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Abstract 
Background: We investigated long-term survival from head and neck cancer using different survival 
approaches.  
Methods: Patients were followed-up from the Scottish Audit of Head and Neck Cancer. Overall and 
disease-specific survival were calculated using the Kaplan-Meier method. Net survival was calculated 
by the Pohar-Perme method. Mutually adjusted Cox proportional hazards models were used to 
determine the predictors of survival.  
Results:  n = 1,820. Overall survival at 12-years was 26.3% (24.3%, 28.3%). Disease-specific survival 
at 12-years was 56.9% (54.3%, 59.4%). Net survival at 12-years was 41.4% (37.6%, 45.1%). 
Conclusion: 26.3% patients were alive 12-years after diagnosis, and the determinants associated 
with long-term survival included age, stage, treatment modality, WHO performance status, alcohol 
consumption, smoking behaviour, and anatomical site.  We recommend that net survival is used for 
long-term outcomes for HNC patients – it disentangles other causes of death, which are 
overestimated in overall survival and underestimated in disease-specific survival. 
Key words: Head and neck cancer; survival; epidemiology; cohort; Scotland 
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Introduction  
Head and neck cancer (HNC) accounted for more than 650,000 new cases and over 350,000 deaths 
worldwide in 2012; and collectively HNC was the sixth most common cancer globally(1). There has 
been an increase in the incidence of HNC in Scotland over the last three decades(2) and in 2015, 
Scotland experienced 1,283 new cases of head and neck cancer(3). Survival for HNC patients in 
Scotland remains poor with little improvement since the 1980’s(4), and over the last ten years, 
mortality rates in Scotland due to HNC have increased by 12% for men and 22% for women(5). 
The influences on overall and disease-specific survival are well described for HNC patients – the 
determinants of short-term survival include age, stage, sex, socioeconomic status, smoking 
behaviour, alcohol consumption, comorbidities(6-9), and, in recent years, human papillomavirus (HPV) 
status which confers a survival advantage(10, 11). Disease recurrence is most likely to occur within the 
first three years, and national guidelines recommend follow-up for five-years after a HNC diagnosis, 
with the aim of detecting early disease recurrence and second primary HNC(12). Few studies focus on 
the long-term outcomes of HNC patients(13, 14), and even less common is the use of net survival in the 
examination of HNC patient survival(15, 16).  
Overall survival considers the risk of death by all causes, whereas disease-specific survival methods 
only consider deaths by the disease of interest and ignores other causes deaths that may have been 
related to or occurred as a secondary effect to the disease of interest(17). Net survival is defined as 
the excess mortality between the observed mortality of the patients under study and the expected 
mortality of the population – this provides a more accurate representation of the mortality from a 
particular disease of interest by disentangling other causes of death, and therefore only measuring 
causes of death that are related to the disease of interest via the use of excess mortality(18, 19).  
The Scottish Audit of Head and Neck Cancer (SAHNC) is a population-based cohort which provides a 
unique opportunity to explore a wide range of factors in association with the long-term survival of 
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HNC patients. This study aims to investigate HNC survival via the use of overall survival, disease-
specific survival and net survival analyses together to provide an in-depth and comprehensive 
picture of the survival of HNC patients. The secondary aim of this paper is to compare different 
survival methods to assess the association of patient, tumour and treatment factors with survival. 
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Materials and Methods 
Patients  
The SAHNC cohort recruited patients between 1st September 1999 and 31st August 2001 – methods 
have previously been described(20-23). During this two-year period, data were recorded on new HNC 
patients diagnosed in Scotland. Quality assurance processes were carried out including cross-
checking the data with medical and pathology results. 
Data Linkage and approvals 
The SAHNC cohort was linked to the National Records of Scotland (NRS) mortality data as at 30th 
September 2013 by ISD Scotland. Records were linked using an established probability matching 
technique based on the Howard Newcombe principle(24) which matches individual patients to their 
national Community Health Index (CHI) number – the unique healthcare identifier used in the 
National Health Service (NHS) in Scotland. Information governance and data linkage approvals were 
obtained from the NHS Privacy Advisory Committee (now known as the Public Benefits and Privacy 
Panel).  
Variables included in analysis 
Patient (age at diagnosis, sex, socioeconomic status (SES), smoking behaviour, alcohol consumption, 
patient performance status), tumour (stage, anatomical site) and treatment (treatment modality, 
geographic location of treatment) factors were all collected at baseline. SES was determined using 
area-based Carstairs Quintiles(25, 26) which ranks patients’ home postcodes into five categories using 
2001 Census socioeconomic data – group 1 represents the most affluent areas and group 5 
represents the most deprived areas. Smoking behaviour (‘current smoker’, ‘previous smoker’ and 
‘never smoked’), and alcohol consumption (‘current problem drinker’, ‘previous problem drinker’ or 
‘occasionally/never drinks’) were determined at the time of diagnosis and no further data were 
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collected on the patient’s habits following diagnosis. Patient performance status was classified at 
diagnosis using the World Health Organisation (WHO) Performance Status (27), which groups patients 
into one of five categories based on their level of physical ability (‘normal activity’, ‘strenuous 
activity restricted’, ‘up and about for more than 50% of waking hours’, ‘confined to a bed or chair for 
more than 50% of waking hours’, and ‘confined to a bed or chair for 100% of waking hours’). Stage 
was determined using the Tumour, Node and Metastases (TNM) Classification of Malignant Tumours 
(28), and the cohort was grouped into stage I,  II,  III or  IV. Anatomical site was classified using the 
International Classification of Disease version 10 (29), grouped into seven categories – lip (C00.9), 
larynx (C32), nasal cavity (C11.9, C30.0, C31), oral cavity (C02–C04, C05.0, C06, C14), oropharynx 
(C01, C05.1–, C09, C10), hypopharynx (C12, C13), and other or salivary gland (C07, C08, C30.1, C41, 
C44, C76, C77). Treatment modality was grouped into seven categories: i) surgery only; ii) 
radiotherapy only; iii) surgery combined with radiotherapy; iv) Surgery, radiotherapy and 
chemotherapy; v) radiotherapy and chemotherapy; vi) chemotherapy with or without surgery; and 
vii) no treatment. Location of treatment was based on the service delivered in the Scottish Cancer 
Networks located in three geographic region – West of Scotland Network (WoSCAN) (which 
comprises health board areas of Ayrshire and Arran, Forth Valley, Greater Glasgow, Clyde and 
Lanarkshire); South East Scotland Cancer Network (SCAN) (Borders, Dumfries and Galloway, Fife, 
Lothian); and North of Scotland Cancer Network (NOSCAN) (Grampian, Highland, Orkney, Shetland, 
Tayside, Western Isles). 
Statistical methods 
Overall and disease-specific survival were calculated using the Kaplan-Meier method with 95% 
confidence intervals (CI’s). Disease-specific survival was computed using death certificates where the 
primary cause of death was recorded as a type of HNC using ICD10 codes. Forward stepwise 
mutually adjusted multivariate Cox proportional hazards models were used to determine the 
variables with an independent association with overall and disease-specific survival – age at 
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diagnosis, cancer stage and treatment modality were forced into the model in the first instance due 
to their strong association with overall and disease-specific survival during unadjusted models (data 
not shown). As a precaution, the results were checked using a backwards stepwise routine, and we 
also performed sensitivity analyses by removing patients with oropharynx cancer or who did not 
receive any treatment. Since this was a large study, many of the p-values were very small and 
therefore, chi-square results have been added to the analysis as a simple way of visually ranking the 
importance of each determinant. All overall survival, disease-specific survival results and Cox 
proportional hazards models were calculated using SAS Software, version 9.4 (SAS Institute Inc., 
USA). Net survival with 95% CIs was calculated by the Pohar-Perme method(30, 31) using life-tables 
provided by the Cancer Survival Group at the London School of Tropical Hygiene and Medicine(32). 
These life-tables were standardised by age, sex and Carstairs 2001 quintile, and were computed 
using the stns command in Stata 14(33, 34). 
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Results  
Cohort recruitment 
 The SAHNC cohort recruited 77% (n = 1,910) of HNC cases that were diagnosed and recorded in the 
Scottish Cancer Registry over the study period from 1st September 1999 to 31st August 2001. Of the 
1,910 patients in the baseline cohort, 1,895 were linked to 12-year mortality records – 15 patients 
were excluded as they were unable to be matched to CHI numbers for data linkage follow-up. A 
further 15 patients were excluded as they were unable to be matched to 2001 Carstairs quintiles and 
60 patients over the age of 85 were also excluded (requirements for the successful computation of 
net survival), which left a remaining total of 1,820 patients included in the analyses. Cause of death 
information was available for all patients from death certificates for disease-specific survival.  
Patient demographics 
 Table 1 outlines the demographic characteristics of the 1,820 patients that were followed up. The 
age at diagnosis ranged from 13 to 85 with a median age of 63 years, and there was a ratio of 2.5:1 
of males to females. The majority of patients were from Carstairs quintiles 4 and 5 areas which 
accounted for more than half of the cohort. Current or previous smoking was reported in 84.6% of 
patients, and 39.0% of patients reported that they were current problem or previous problem 
drinkers. The most common anatomical site was the larynx, followed by the oral cavity, and 79.3% of 
patients were treated by either 'surgery only', 'radiotherapy only' or 'surgery and radiotherapy'. 
55.0% of patients were treated in the West of Scotland, and a total of 1,384 (76.0%) of patients had 
died by September 2013.  
Comparison of overall, disease-specific and net survival results 
Overall, disease-specific and net survival proportions at one and 12-years for each of the patient, 
tumour and treatment factors are displayed in Table 2. Overall survival at one and 12-years was 
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76.0% (74.0%, 77.9%) and 26.3% (24.3%, 28.3%), respectively. Disease-specific survival at one- and 
12-years was 82.3% (80.4%, 84.0%) and 56.9% (54.3%, 59.4%), respectively. Net survival at one- and 
12-years was 78.3% (76.2%, 80.3%) and 41.4% (37.6%, 45.1%), respectively. One year after follow-
up, males and females had approximately the same survival for all three measurements of survival; 
however, by 12-years males consistently had the lowest survival. At one year, there were clear 
gradients in survival by SES with the patients from the most affluent areas experiencing the highest 
survival for overall (83.4%, (78.1%, 87.5%)), disease-specific (88.0%, (83.9%, 92.2%)) and net (86.1%, 
(81.3%, 91.0%)) survival. By 12-years, these gradients were not as clear cut, however differences 
between those from the most affluent and the most deprived areas continued to exist, with patients 
from the most deprived areas having the lowest survival outcomes for overall, disease-specific and 
net survival than any other quintile.  Patients who had never smoked had a survival advantage 
compared to the patients who were either current or previous smokers when using the overall, 
disease-specific and net survival methods, particularly by 12-years for patients who had never 
smoked with a net survival estimate of 70.6% (57.1%, 84.1%) compared with 32.4% (28.6%, 36.2%) 
for current smokers. Current and previous problem drinkers had approximately the same survival 
throughout all three methods of survival, which was substantially higher by 12-years for current 
problem drinkers using the disease-specific method (45.9% (40.5%, 51.1%)) compared to using the 
overall (18.2%, 95% CIs 14.9%, 21.7%) and net (23.5% (18.6%, 28.4%) survival methods. Those with 
normal activity levels had higher survival than patients who did not have normal activity levels using 
all three methods of survival. One year after diagnosis, patients with tumours of the lip experienced 
the highest overall (94.1%, 95% CIs 86.4, 97.5%), disease-specific  (97.6%, (90.8%, 99.4%)) and net  
(97.7%, (92.4%, 100.3%)) survival, however this reduced substantially to 56.5% (45.3%, 66.2%) at 12-
years using the overall survival method, but did not reduce significantly using the disease-specific or 
net survival methods, suggesting these patients are dying of other causes. Clear trends can be seen 
by stage for all three survival methods with those of stage I experiencing the highest survival. 
Patients who were treated with surgery alone experienced the highest overall, disease-specific and 
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net survival results, whereas patients who were treated in the West of Scotland network region 
generally had the lowest results. There were clear differences between overall, disease-specific and 
net survival results, with the disease-specific method presenting the highest outcome, followed by 
the net survival method and, as expected, the overall survival method displayed the lowest results.  
Mutually adjusted Cox proportional hazards models for overall and disease-specific survival 
Mutually adjusted Cox proportional hazards models are displayed in Table 3 using the overall 
survival method, and Table 4 using the disease-specific survival method. In the order of which they 
were entered into the model, the determinants with an independent association with overall 
survival at both one and 12-years included age at diagnosis, cancer stage, treatment modality, WHO 
Performance Status, alcohol consumption, anatomical site and smoking status. Results for the 
mutually adjusted Cox proportional hazards models using disease-specific survival varied slightly – 
the determinants associated with disease-specific survival at one year included age at diagnosis, 
cancer stage, treatment modality, WHO Performance Status, network and alcohol consumption; 
however the determinants associated with 12-years disease-specific survival included age at 
diagnosis, cancer stage, treatment modality, WHO Performance status, alcohol consumption and 
anatomical site – interestingly, smoking was not an independent predictor for disease-specific 
survival at either time points. These results were also obtained when running a backwards 
elimination method, and similar models were achieved when patients with oropharynx cancer and 
patients who did not receive treatment were removed (Supplementary Tables 1 and 2).  
Discussion  
Overall survival at one- and 12-years was 76.0% (74.0%, 77.9%) and 26.3% (24.3%, 28.3%), 
respectively, while disease-specific survival was higher at both one- and 12-years at   82.3% (80.4%, 
84.0%) and 56.9% (54.3%, 59.4%), respectively. Net survival estimates for one- and 12-years were 
78.3% (76.2%, 80.3%) and 41.4% (37.6%, 45.1%), respectively. Following mutual adjustment, overall 
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survival of HNC patients was associated with age at diagnosis, cancer stage, treatment modality, 
WHO Performance Status, alcohol consumption, anatomical site and smoking status, and disease-
specific survival was associated with age at diagnosis, cancer stage, treatment modality, WHO 
Performance Status, and alcohol consumption, with the addition of network at one-year and 
anatomical site by 12 years.  
The association of stage reflects disease-specific deaths, whereas WHO performance status may be a 
representation of comorbidities in the cohort of patients, which have been described to have a 
negative impact on the survival of HNC patients(35). Similarly, associations with smoking and alcohol 
behaviours are common risk factors for HNC, and patients often present with many significant 
comorbidities including chronic obstructive pulmonary disease, heart disease, liver disease and 
secondary cancers(36). The strong association of treatment is likely to reflect those who received 
palliative care – particularly due to the inclusion of the patients who received 'no treatment', 
however sensitivity analyses excluding the patients who received no treatment generated similar 
results (Supplementary Table 1). The variance in survival of patients by anatomical site may be 
influenced by the inclusion of patients with cancer of the lip, who consistently had substantially 
improved survival compared with patients with cancers of other HNC sites.  
There was a substantial difference between overall survival, disease-specific survival and net survival 
estimates in this study. Overall survival overestimates deaths as a result of HNC since all causes of 
death are considered in this measurement, whereas disease-specific survival may be an unreliable 
estimate when using death certificates as exact causes of death are often unclear. The difference 
between overall and disease-specific results suggest that patients are dying of other HNC-related 
causes, but these causes are not as a direct result of HNC and are therefore not documented on 
death certificates. Net survival estimates background mortality using a group of patients with the 
same demographics as the patient in the study and calculates the excess death that has occurred as 
a result of the disease of interest. There is no need to use death certificates to compute this 
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measurement and thus there is little inaccuracy as to the cause of death in the patient.  Therefore, 
we feel that the use of net survival provides a good compromise to traditional methods, particularly 
in long-term studies, to estimate the true burden of HNC-specific deaths.  
Over the last two decades, there has been an increase in the incidence of HNCs that are associated 
with HPV(2, 37, 38). This is particularly common for patients with cancer of the oropharynx for whom 
around one to two thirds of tumours may be HPV-driven(39), suggesting that one limitation of this 
study is the absence of HPV data. Patients with HPV-positive tumours have considerably better 
prognoses than patients with HPV-negative tumours, even following adjustment for other baseline 
covariates(40, 41). The primary focus of these analyses was to investigate the long-term survival of HNC 
patients from Scotland diagnosed between the years of 1999 and 2001. The baseline data collection 
for this study was ahead of the mainstream discovery of the association of HPV with HNC(42) and 
therefore HPV data were not routinely collected or available in this study. However, aside from 
oropharynx patients, the majority of HNC diagnosed today are HPV-negative and these tumours are 
likely to be smoking- and alcohol-related(43, 44), and previous studies suggest that smoking, alcohol, 
and HPV are three independent risk factors of HNC survival(45, 46). Furthermore, the oropharyngeal 
patients in this study did not exhibit the clear survival advantage that is usually observed for HPV-
associated oropharyngeal cancer(41). Sensitivity analyses involving the exclusion of patients with 
oropharynx cancer demonstrated similar results (Supplementary Table 2), however, we were unable 
to separate out patients with HPV positive tumour. Therefore, the SAHNC patients’ cancers are likely 
to be predominantly related to smoking and problem alcohol behaviours and we propose that our 
findings remain relevant to clinicians, researchers and other health professionals in gaining an 
understanding of the long-term prognosis of patients with non-HPV driven HNC, particularly since 
the prevalence of smoking and problem alcohol consumption was very high in this study.  
The SAHNC cohort also pre-dates the use of organ preservation strategies that were introduced in 
Scotland in 2006(47). However, studies following the introduction of these practices outline the 
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importance of ensuring clear margins in surgery in the treatment of HNC(48, 49). Therefore, due to the 
high proportion of patients being treated with surgery in the SAHNC cohort, this study also remains 
relevant and may be used in treatment planning decisions for HNC patients. Moreover, these 
analyses were based on historical cases (1999 to 2001), which is a prerequisite for estimating long-
term follow-up, which we would argue is a strength of the SAHNC cohort.    
The SAHNC cohort represented 77% of all HNC cases on the Scottish Cancer Registry over a two-year 
period and was representative of HNC cases in Scotland. Previous analyses of the SAHNC cohort 
have outlined five-year overall and disease-specific survival(20-23). This study adds to the worldwide 
literature on long-term HNC survival, and provides an in-depth analysis of overall, disease-specific 
and net survival of HNC patients using a national clinical cohort. This study also supports the use of 
net survival, particularly in analyses with long-term follow-up.   
Conclusion 
Overall survival at one- and 12-years was 76.0% (74.0%, 77.9%) and 26.3% (24.3%, 28.3%), 
respectively, while disease-specific survival was higher at both one- and 12-years at 82.3% (80.4%, 
84.0%) and 56.9% (54.3%, 59.4%), respectively. Following mutual adjustment, overall and disease-
specific survival for HNC patients was associated with age at diagnosis, cancer stage, treatment 
modality, WHO Performance Status, alcohol consumption, anatomical site, smoking status and 
cancer network. Net survival estimates for one- and 12-years were 78.3% (76.2%, 80.3%) and 41.4% 
(37.6%, 45.1%), respectively. The substantial difference between overall survival, disease-specific 
survival and net survival demonstrates the overestimation of HNC-specific deaths when using overall 
survival, and the underestimation of disease-specific mortality when using death certificates where 
patients have died only from HNC. These results suggest that patients are dying of other causes that 
are related to their HNC but are not as a direct result of HNC. Therefore, the use of net survival 
seems to provide a good compromise to traditional methods to estimate the true burden of HNC in 
long-term follow-up studies.  
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Table 1 – Frequency of all patient, tumour and treatment characteristics and frequency of deaths for all cases  
Variable 
Frequency  
(Column %) 
Died by September 2013 
No (Row %) Yes (Row %) 
Total 1,820 (100.0%) 436 (24.0%) 1,384 (76.0%) 
Age at diagnosis    
   Less than 45 99 (5.4%) 61 (61.6%) 38 (38.4%) 
   45 to 54 288 (15.8%) 105 (36.5%) 183 (63.5%) 
   55 to 64 592 (32.5%) 166 (28.0%) 426 (72.0%) 
   65 to 74 551 (30.3%) 81 (14.7%) 470 (85.3%) 
   75 and over 290 (15.9%) 23 (8.0%) 267 (92.1%) 
Sex    
   Male 1,300 (71.4%) 300 (23.1%) 1,000 (76.9%) 
   Female 520 (28.6%) 136 (26.2%) 384 (73.9%) 
Carstairs quintile    
   1 (Most affluent) 241 (13.2%) 58 (24.1%) 183 (75.9%) 
   2 317 (17.4%) 91 (28.7%) 226 (71.3%) 
   3 325 (17.9%) 77 (23.7%) 248 (76.3%) 
   4 409 (22.5%) 98 (24.0%) 311 (76.0%) 
   5 (Most deprived) 528 (29.0%) 112 (21.2%) 416 (78.8%) 
Smoking behaviour     
   Current smoker 1,134 (62.3%) 228 (21.0%) 906 (79.9%) 
   Previous smoker 405 (22.3%) 104 (25.7%) 301 (74.3%) 
   Never smoked 221 (12.1%) 88 (39.8%) 133 (60.2%) 
   Not recorded 60 (3.3%) 16 (26.7%) 44 (73.3%) 
Alcohol consumption    
   Current problem drinker 496 (27.3%) 86 (17.3%) 410 (82.7%) 
   Previous problem drinker 212 (11.7%) 32 (15.1%) 180 (84.9%) 
   Occasionally/never drinks 891 (49.0%) 262 (29.4%) 629 (70.6%) 
   Not recorded 221 (12.1%) 56 (25.3%) 165 (74.7%) 
WHO Performance Status    
   Normal activity 825 (45.3%) 314 (38.1%) 511 (61.9%) 
   Strenuous activity restricted 465 (25.6%) 64 (13.8%) 401 (86.2%) 
   Up and about >50% 137 (7.5%) 7 (5.1%) 130 (94.9%) 
   Confined to bed/chair >50%  97 (5.3%) 1 (1.0%) 96 (99.0%) 
   Not recorded 296 (16.3%) 50 (16.9%) 246 (83.1%) 
Anatomical site    
   Lip 85 (4.7%) 45 (52.9%) 40 (47.1%) 
   Larynx 584 (32.1%) 157 (26.9%) 427 (73.1%) 
   Nasal cavity 85 (4.7%) 21 (24.7%) 64 (75.3%) 
   Oral cavity 506 (28.8%) 111 (21.9%) 395 (78.1%) 
   Oropharynx 323 (17.8%) 62 (19.2%) 261 (80.8%) 
   Hypopharynx 119 (6.5%) 7 (5.9%) 112 (94.1%) 
   Other/salivary gland 118 (6.5%) 33 (28.0%) 85 (72.0%) 
Stage    
   I 383 (21.0%) 165 (43.1%) 218 (56.9%) 
   II 369 (20.3%) 103 (27.9%) 266 (72.1%) 
   III 273 (15.0%) 60 (22.0%) 213 (78.0%) 
   IV 662 (36.4%) 76 (11.5%) 586 (88.5%) 
   Unknown 133 (7.3%) 32 (24.1%) 101 (75.9%) 
Treatment modality    
   Surgery only 477 (26.2%) 164 (34.4%) 313 (65.6%) 
   Radiotherapy only 507 (27.9%) 130 (25.6%) 377 (74.4%) 
   Surgery + radiotherapy 458 (25.2%) 98 (21.4%) 360 (78.6%) 
   Surgery, radiotherapy + chemotherapy 65 (3.6%) 20 (4.6%) 45 (3.3%) 
   Radiotherapy + chemotherapy 143 (7.9%) 21 (4.8%) 122 (8.8%) 
   Chemotherapy +/- surgery 41 (2.3%) 1 (0.2%) 40 (2.9%) 
   No treatment 129 (7.1%) 2 (1.6%) 127 (98.5%) 
Network/region    
   WoSCAN (West of Scotland) 1,001 (55.0%) 214 (21.4%) 787 (78.6%) 
   SCAN (East of Scotland) 440 (24.2%) 124 (28.2%) 316 (71.8%) 
   NOSCAN (North of Scotland) 379 (20.8%) 98 (25.9%) 281 (74.1%) 
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 Table 2 – One- and 12-year overall, net and disease-specific survival for all patient, tumour and treatment factors  
 Overall  Disease-specific  Net  
Variable 1-year 12-years 1-year 12-year 1-year 12-year 
Whole cohort 76.0 (74.0, 77.9) 26.3 (24.3, 28.3) 82.3 (80.4, 84.0) 56.9 (54.3, 59.4) 78.3 (76.2, 80.3) 41.4 (37.6, 45.1) 
Age at diagnosis       
  Less than 45 90.9 (83.3, 95.2) 62.6 (52.3, 71.3) 94.8 (88.0, 97.8) 72.1 (61.7, 80.1) 91.1 (85.5, 96.8) 64.9 (55.0, 74.7) 
  45 to 54 83.7 (78.9, 87.5) 37.5 (31.9, 43.0) 86.5 (81.9, 90.0) 60.2 (53.8, 66.0) 84.2 (80.0, 88.6) 42.2 (35.9, 48.5) 
  55 to 64 78.4 (74.8, 81.5) 30.2 (26.6, 34.0) 83.1 (79.7, 85.9) 60.0 (55.5, 64.2) 79.6 (76.2, 83.0) 38.8 (34.0, 43.7) 
  65 to 74 73.1 (69.2, 76.6) 18.0 (14.9, 21.3) 81.7 (78.1, 84.8) 54.2 (49.1, 59.1) 75.9 (72.1, 79.8) 35.8 (29.5, 42.2) 
  75 and over 64.1 (58.3, 69.4) 10.3 (7.2, 14.2) 72.9 (67.2, 77.8) 45.3 (37.9, 52.4) 69.1 (63.2, 75.0) 43.2 (28.0, 58.4) 
Sex       
  Male 76.2 (73.7, 78.4) 24.9 (22.6, 27.3) 82.0 (79.8, 84.1) 55.3 (52.2, 58.3) 78.5 (76.1, 80.9) 40.5 (36.2, 44.8) 
  Female 75.8 (71.9, 79.2) 29.6 (25.8, 33.6) 82.8 (79.2, 85.9) 60.9 (56.0, 65.5) 77.6 (73.8, 81.4) 43.0 (36.1, 49.8) 
Carstairs quintile       
  1 (Most affluent) 83.4 (78.1, 87.5) 27.0 (21.5, 32.7) 88.8 (83.9, 92.2) 61.8 (54.4, 68.4) 86.1 (81.3, 91.0) 40.4 (30.7, 50.0) 
  2 78.6 (73.6, 82.7) 30.6 (25.6, 35.7) 83.2 (78.5, 86.9) 65.6 (59.6, 70.9) 80.9 (76.2, 85.5) 43.8 (35.0, 52.6) 
  3 76.3 (71.3, 80.6) 26.2 (21.5, 31.0) 82.2 (77.5, 86.1) 55.5 (49.2, 61.3) 78.6 (73.8, 83.3) 40.7 (31.5, 49.9) 
  4 75.1 (70.6, 79.0) 26.9 (22.7, 31.3) 81.8 (77.5, 85.3) 55.5 (49.9, 60.8) 77.2 (72.8, 81.5) 46.6 (38.4, 54.7) 
  5 (Most deprived) 71.8 (67.8, 75.4) 22.9 (19.4, 26.5) 79.1 (75.2, 82.4) 51.1 (46.0, 55.9) 73.7 (69.7, 77.6) 35.7 (29.6, 41.8) 
Smoking behaviour       
  Current smoker 72.8 (70.1, 75.2) 22.3 (19.9, 24.8) 79.0 (76.4, 81.3) 53.2 (49.9, 56.5) 74.6 (71.9, 77.2) 32.4 (28.6, 36.2) 
  Previous smoker 80.3 (76.0, 83.8) 27.4 (23.2, 31.8) 87.0 (83.2, 90.0) 59.8 (54.1, 65.0) 83.3 (79.2, 87.3) 49.9 (40.5, 59.2) 
  Never smoked 85.5 (80.2, 89.5) 43.9 (37.3, 50.3) 89.3 (84.4, 92.8) 66.9 (59.8, 73.0) 87.9 (83.1, 92.7) 70.6 (57.1, 84.1) 
  Not recorded 75.0 (62.0, 84.1) 28.3 (17.6, 40.0) 86.0 (73.9, 92.7) 67.3 (51.2, 79.1) 77.6 (66.2, 88.9) 40.3 (22.2, 58.5) 
Alcohol consumption       
  Current problem drinker 70.8 (66.6, 74.6) 18.2 (14.9, 21.7) 77.8 (73.7, 81.3) 45.9 (40.5, 51.1) 72.4 (68.3, 76.5) 23.5 (18.6, 28.4) 
  Previous problem drinker 72.2 (65.6, 77.7) 17.0 (12.3, 22.3) 76.6 (70.2, 81.8) 49.7 (42.1, 56.9) 74.0 (67.9, 80.2) 23.4 (15.9, 30.9) 
  Occasional/never 79.2 (76.4, 81.8) 32.3 (29.3, 35.4) 85.0 (82.4, 87.2) 62.1 (58.5, 65.5) 81.7 (78.9, 84.4) 54.1 (48.0, 60.1) 
  Not recorded 78.7 (72.7, 83.6) 29.0 (23.1, 35.0) 86.7 (81.2, 90.6) 65.4 (57.6, 72.1) 81.3 (75.7, 86.9) 43.9 (33.8, 54.0) 
WHO Performance Status       
  Normal activity 88.1 (85.7, 90.2) 40.6 (37.2, 43.9) 91.9 (89.8, 92.6) 70.4 (66.8, 73.7) 90.2 (88.0, 92.5) 59.0 (53.5, 64.9) 
  Strenuous restricted 72.3 (68.0, 76.1) 16.1 (13.0, 19.6) 79.1 (74.9, 82.6) 49.7 (44.1, 55.0) 74.6 (70.5, 78.9) 33.1 (26.7, 41.1) 
  Up and about >50%  50.4 (41.7, 58.4) 7.3 (3.7, 12.5) 62.0 (52.7, 70.0) 30.3 (21.2, 40.0) 52.2 (44.2, 61.6) 11.6 (5.9, 22.9) 
  Confined >50%  34.0 (24.8, 43.4) 1.0 (0.1, 5.0) 44.8 (33.7, 55.2) 10.1 (2.8, 23.1) 35.6 (27.0, 46.8) 1.5 (0.3, 9.0) 
  Not recorded 74.0 (68.6, 78.6) 19.3 (15.0, 23.9) 79.2 (74.0, 83.5) 50.2 (43.4, 56.7) 76.5 (71.5, 81.8) 31.2 (23.7, 41.1) 
Anatomical site       
  Lip 94.1 (86.4, 97.5) 56.5 (45.3, 66.2) 97.6 (90.8, 99.4) 91.3 (81.5, 96.0) 97.7 (92.4, 100.3) 98.3 (76.3, 120.2) 
  Larynx 81.9 (78.5, 84.8) 29.5 (25.8, 33.2) 85.9 (82.8, 88.5) 63.8 (59.2, 67.9) 84.4 (81.1, 87.6) 50.5 (43.4, 57.7) 
  Nasal cavity 77.7 (67.2, 85.1) 25.9 (17.1, 35.5) 82.8 (72.6, 89.4) 52.6 (40.2, 63.6) 79.5 (70.4, 88.5) 31.9 (19.5, 44.4) 
  Oral cavity 76.9 (67.2, 85.1) 23.7 (20.1, 27.5) 82.1 (78.4, 85.3) 55.4 (50.3, 60.3) 79.1 (75.3, 82.9) 36.8 (30.1, 43.6) 
  Oropharynx 65.3 (59.9, 70.2) 21.4 (17.1, 26.0) 73.8 (68.5, 78.4) 45.8 (39.6, 51.8) 66.7 (61.4, 72.0) 25.7 (19.7, 31.8) 
  Hypopharynx 55.5 (46.1, 63.9) 9.2 (4.9, 15.3) 68.4 (58.5, 76.4) 23.6 (14.5, 33.9) 57.0 (47.9, 66.2) 15.8 (7.0, 24.7) 
  Other/salivary gland 79.7 (71.2, 85.9) 30.5 (22.5, 38.9) 87.7 (80.2, 92.6) 62.3 (51.0, 71.7) 81.6 (74.1, 89.0) 44.8 (29.9, 59.7) 
Stage       
  I 97.1 (94.9, 98.4) 46.0 (40.9, 50.9) 98.7 (96.9, 99.5) 84.0 (79.4, 87.8) 99.9 (98.2, 101.7) 72.2 (62.7, 81.6) 
  II 89.2 (85.5, 91.9) 30.4 (25.7, 35.1) 93.3 (90.2, 95.5) 65.6 (59.6, 70.9) 91.9 (88.6, 95.2) 51.8 (42.8, 60.9) 
  III 74.7 (69.1, 79.5) 23.8 (18.9, 29.0) 81.7 (76.4, 85.9) 53.4 (46.2, 60.0) 76.6 (71.3, 81.9) 32.7 (24.4, 41.0) 
  IV 57.6 (53.7, 61.2) 13.9 (11.4, 16.7) 66.2 (62.4, 69.8) 35.3 (31.0, 39.6) 59.1 (55.2, 63.0) 21.6 (17.1, 26.0) 
  Unknown 73.7 (65.3, 80.3) 24.8 (17.9, 32.4) 80.3 (72.2, 86.2) 55.4 (45.4, 64.3) 76.2 (68.5, 83.9) 36.8 (24.5, 49.1) 
Treatment modality        
  Surgery only 88.9 (85.7, 91.4) 36.7 (32.4, 41.0) 93.5 (90.8, 95.4) 72.8 (68.1, 77.0) 91.7 (88.8, 94.6) 61.7 (53.1, 70.2) 
  Radiotherapy only 82.1 (78.4, 85.1) 27.6 (23.8, 31.6) 87.0 (83.7, 89.7) 63.1 (58.1, 67.7) 84.8 (81.3, 88.2) 44.3 (37.0, 51.5) 
  Surgery + radio 83.0 (79.2, 86.1) 24.9 (21.0, 28.9) 86.4 (82.9, 89.3) 54.2 (48.8, 59.3) 84.9 (81.4, 88.5) 36.2 (29.7, 42.6) 
   Surgery, radio + chemo 69.2 (56.5, 78.9) 32.3 (21.4, 43.7) 70.7 (58.0, 80.2) 47.3 (34.3, 59.2) 70.5 (59.2, 81.9) 39.4 (23.4, 55.5) 
   Radio + chemo 70.6 (62.4, 77.4) 17.5 (11.8, 23.1) 77.5 (69.6, 83.6) 37.3 (28.3, 46.3) 72.0 (64.4, 79.6) 22.3 (13.8, 30.8) 
   Chemo +/- surgery 9.8 (3.1, 21.0) 2.4 (0.2, 11.0) 17.2 (5.6, 34.0) 4.3 (0.3, 17.9) 10.0 (1.3, 18.7) 2.6 (1.5, 6.8) 
  No Treatment 10.9 (6.2, 16.9) 1.6 (0.3, 5.0) 18.1 (10.7, 26.9) 5.6 (1.7, 13.1) 11.2 (6.8, 16.7) 1.7 (0.4, 3.9) 
Network/region       
  WoSCAN (West Scotland) 75.3 (72.5, 77.9) 24.0 (21.4, 26.7) 82.5 (79.9, 84.8) 54.8 (51.1, 58.3) 77.4 (74.7, 80.2) 36.9 (32.0, 41.7) 
  SCAN (East Scotland) 76.4 (72.1, 80.1) 30.0 (25.8, 34.3) 82.0 (78.0, 85.4) 60.0 (54.8, 64.8) 78.7 (74.6, 82.8) 50.0 (42.0, 58.1) 
  NOSCAN (North Scotland) 77.6 (73.0, 81.5) 28.0, (23.5, 32.6) 81.9 (77.6, 85.5) 58.6 (52.9, 63.8) 79.7 (75.4, 84.0) 41.9 (34.7, 49.2) 
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Table 3 – Mutually adjusted forward stepwise Cox proportional hazard ratios at one- and 12-years for all patient, tumour 
and treatment factors for overall survival 
 One-year    12-year    
Variable HR (95% CIs) HR p-value p-value Chi-Sq. HR (95% CIs) HR p-value p-value Chi-Sq. 
Age at diagnosis   <0.001 22.23   <0.001 139.21 
  Less than 45 0.71 (0.42, 1.21) 0.208   0.59 (0.42, 0.84) 0.004   
  45 to 54 1.00 (Ref.) -   1.00 (Ref.) -   
  55 to 64 1.00 (0.77, 1.29) 0.991   1.17 (0.98, 1.40) 0.077   
  65 to 74 1.37 (1.05, 1.79) 0.019   1.94 (1.62, 2.32) <0.001   
  75 and over 1.60 (1.18, 2.18) 0.002   2.44 (1.97, 3.01) <0.001   
Smoking behaviour   0.024 9.40   <0.001 24.62 
  Current smoker 1.42 (1.04, 1.94) 0.026   1.45 (1.19, 1.77) <0.001   
  Previous smoker 1.12 (0.80, 1.56) 0.520   1.08 (0.87, 1.34) 0.488   
  Never smoked 1.00 (Ref.) -   1.00 (Ref.) -   
  Not recorded 0.94 (0.51, 1.73) 0.835   1.22 (0.83, 1.80) 0.304   
Alcohol consumption   0.023 10.82   <0.001 38.81 
  Current problem drinker 1.32 (1.08, 1.61) 0.006   1.51 (1.31, 1.73) <0.001   
  Previous problem drinker 1.19 (0.93, 1.53) 0.169   1.36 (1.15, 1.62) <0.001   
  Occasional/never 1.00 (Ref.) -   1.00 (Ref.) -   
  Not recorded 0.86 (0.63, 1.16) 0.323   1.01 (0.83, 1.23) 0.900   
WHO Performance Status   <0.001 41.46   <0.001 84.55 
  Normal activity 1.00 (Ref.) -   1.00 (Ref.) -   
  Strenuous restricted 1.52 (1.23, 1.89) <0.001   1.46 (1.27, 1.68) <0.001   
  Up and about >50%  2.19 (1.66, 2.90) <0.001   2.13 (1.73, 2.63) <0.001   
  Conf. to bed/chair >50%  2.38 (1.74, 3.27) <0.001   2.61 (2.03, 3.36) <0.001   
  Not recorded 1.45 (1.13, 1.85) 0.003   1.42 (1.21, 1.66) <0.001   
Anatomical site   0.006 18.33   <0.001 32.79 
  Lip 0.48 (0.23, 1.03) 0.058   0.50 (0.35, 0.73) <0.001   
  Larynx 0.72 (0.57, 0.91) 0.007   0.74 (0.63, 0.88) <0.001   
  Nasal cavity 0.80 (0.54, 1.20) 0.279   0.78 (0.59, 1.04) 0.087   
  Oral cavity 1.00 (0.79, 1.27) 0.991   0.98 (0.82, 1.16) 0.790   
  Oropharynx 1.00 (Ref.) -   1.00 (Ref.) -   
  Hypopharynx 0.99 (0.74, 1.31) 0.926   1.06 (0.84, 1.33) 0.624   
  Other/salivary gland 1.25 (0.88, 1.77) 0.210   1.02 (0.79, 1.33) 0.881   
Stage   <0.001 22.23   <0.001 83.57 
  I 1.00 (Ref.) -   1.00 (Ref.) -   
  II 2.71 (1.81, 4.05) <0.001   1.44 (1.20, 1.73) <0.001   
  III 4.17 (2.77, 6.27) <0.001   1.77 (1.45, 2.17) <0.001   
  IV 5.89 (3.98, 8.71) <0.001   2.38 (1.97, 2.88) <0.001   
  Unknown 4.36 (2.74, 6.95) <0.001   1.97 (1.52, 2.56) <0.001   
Treatment modality    <0.001 285.18   <0.001 283.86 
  Surgery only 1.00 (Ref.) -   1.00 (Ref.) -   
  Radiotherapy only 1.62 (1.22, 2.56) <0.001   1.31 (1.09, 1.57) 0.004   
  Surgery + radio 0.97 (0.73, 1.29) 0.828   1.02 (0.86, 1.22) 0.810   
   Surgery, radio + chemo 1.39 (0.88, 2.19) 0.154   1.00 (0.72, 1.39) 0.984   
   Radio + chemo 1.70 (1.21, 2.40) 0.002   1.40 (1.10, 1.78) 0.006   
   Chemo +/- surgery 7.25 (4.77, 11.02) <0.001   6.01 (4.19, 8.62) <0.001   
  No Treatment 7.78 (5.68, 10.66) <0.001   5.99 (4.67, 7.69) <0.001   
- Reference category 
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Table 4 – Mutually adjusted one- and 12-year overall for all patient, tumour and treatment factors for disease-specific 
survival 
 1-year    12-year    
Variable HR (95% CIs) HR p-value p-value Chi-Sq. HR (95% CIs) HR p-value p-value Chi-Sq. 
Age at diagnosis   0.018 11.93   <0.001 22.85 
  Less than 45 0.70 (0.38, 1.27) 0.236   0.78 (0.51, 1.21) 0.267   
  45 to 54 1.00 (Ref.) -   1.00 (Ref.) -   
  55 to 64 0.89 (0.66, 1.20) 0.432   0.94 (0.74, 1.19) 0.607   
  65 to 74 1.03 (0.76, 1.40) 0.856   1.28 (0.99, 1.64) 0.056   
  75 and over 1.41 (1.00, 2.00) 0.053   1.58 (1.18, 2.11) 0.002   
Alcohol consumption   <0.001 19.33   <0.001 30.95 
  Current problem drinker 1.42 (1.13, 1.78) 0.002   1.54 (1.28, 1.86) <0.001   
  Previous problem drinker 1.35 (1.01, 1.80) 0.041   1.42 (1.12, 1.80) 0.004   
  Occasional/never 1.00 (Ref.) -   1.00 (Ref.) -   
  Not recorded 0.69 (0.48, 0.97) 0.035   0.81 (1.15, 1.07) 0.131   
WHO Performance Status   <0.001 31.61   <0.001 43.93 
  Normal activity 1.00 (Ref.) -   1.00 (Ref.) -   
  Strenuous restricted 1.60 (1.23, 2.09) <0.001   1.41 (1.15, 1.73) 0.001   
  Up and about >50%  2.25 (1.60, 3.15) <0.001   2.06 (1.55, 2.74) <0.001   
  Conf. to bed/chair >50%  2.51 (1.72, 3.66) <0.001   2.66 (1.92, 3.68) <0.001   
  Not recorded 1.51 (1.11, 2.04) 0.008   1.46 (1.16, 1.84) 0.001   
Anatomical site   / /   0.005 18.47 
  Lip / /   0.25 (0.11, 0.58) 0.001   
  Larynx / /   0.78 (0.61, 0.99) 0.037   
  Nasal cavity / /   0.82 (0.56, 1.20) 0.314   
  Oral cavity / /   0.98 (0.78, 1.25) 0.885   
  Oropharynx / /   1.00 (Ref.) -   
  Hypopharynx / /   1.10 (0.82, 1.47) 0.531   
  Other/salivary gland / /   0.80 (0.54, 1.18) 0.259   
Stage   <0.001 84.00   <0.001 98.22 
  I 1.00 (Ref.) -   1.00 (Ref.) -   
  II 4.89 (2.62, 9.12) <0.001   2.13 (1.52, 2.98) <0.001   
  III 7.23 (3.85, 13.57) <0.001   3.03 (2.14, 4.29) <0.001   
  IV 12.42 (6.77, 22.83)  <0.001   4.86 (3.49, 6.77) <0.001   
  Unknown 7.86 (3.99, 15.51) <0.001   3.83 (2.52, 5.83) <0.001   
Treatment modality    <0.001 233.82   <0.001 205.62 
  Surgery only 1.00 (Ref.) -   1.00 (Ref.) -   
  Radiotherapy only 1.70 (1.21, 2.38) 0.002   1.54 (1.17, 2.03) 0.002   
  Surgery + radio 1.12 (0.79, 1.59) 0.532   1.14 (0.88, 1.49) 0.325   
   Surgery, radio + chemo 2.08 (1.26, 3.42) 0.004   1.45 (0.95, 2.21) 0.084   
   Radio + chemo 2.13 (1.42, 3.19) <0.001   1.77 (1.28, 2.45) <0.001   
   Chemo +/- surgery 7.27 (4.41, 12.00) <0.001   6.49 (4.10, 10.26) <0.001   
  No Treatment 10.15 (6.93, 14.87) <0.001   7.71 (5.54, 10.73) <0.001   
Network/region   0.043 6.29   / / 
  WoSCAN (West Scotland) 0.95 (0.74, 1.20)    / /   
  SCAN (East Scotland) 1.00 (Ref.) -   / /   
  NOSCAN (North Scotland) 1.30 (0.98, 1.73)    / /   
- Reference category 
/ Not entered into model 
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Supplementary Tables 
 
Supplementary Table 1 - Mutually adjusted Cox proportional hazards model results when excluding patients who received no treatment (n = 1,691) 
Overall      Disease-specific      
1-year p-value Chi-Sq. 12-year p-value Chi-Sq. 1-year p-value Chi-Sq. 12-year p-value Chi-Sq. 
Age <0.001 24.45 Age <0.001 140.09 Age 0.110 7.54 Age <0.001 18.93 
Stage <0.001 102.76 Stage <0.001 90.68 Stage <0.001 86.82 Stage <0.001 104.10 
Treatment <0.001 46.79 Treatment <0.001 25.34 Treatment <0.001 38.60 Treatment <0.001 28.04 
WHO <0.001 46.77 WHO <0.001 93.65 WHO <0.001 32.13 WHO <0.001 51.71 
Alcohol  0.004 13.52 Alcohol <0.001 34.77 Alcohol 0.001 15.82 Site <0.001 34.07 
Site <0.001 30.47 Site <0.001 42.66 Site 0.007 17.62 Alcohol <0.001 25.90 
Smoking 0.022 9.65 Smoking <0.001 27.49 Network 0.050 5.99 - - - 
 
 
Supplementary Table 2 - Mutually adjusted Cox proportional hazards model results when excluding oropharynx patients (n = 1,497) with larynx as new reference group 
Step Overall      Disease-specific      
1 1-year p-value Chi-Sq. 12-year p-value Chi-Sq. 1-year p-value Chi-Sq. 12-year p-value Chi-Sq. 
2 Age 0.008 13.88 Age <0.001 102.99 Age 0.015 12.30 Age 0.003 16.53 
3 Stage <0.001 81.75 Stage <0.001 84.89 Stage <0.001 67.36 Stage <0.001 89.54 
4 Treatment <0.001 177.34 Treatment <0.001 155.18 Treatment <0.001 149.20 Treatment <0.001 119.32 
5 WHO < 0.001 45.10 WHO <0.001 86.31 WHO <0.001 32.06 WHO <0.001 50.11 
6 Alcohol  0.007 12.24 Alcohol <0.001 31.70 Alcohol 0.001 16.03 Alcohol <0.001 23.22 
7 Site 0.008 15.50 Site <0.001 29.65 Network 0.004 11.14 Site 0.003 18.04 
8 Network 0.028 7.17 Smoking <0.001 16.39 - - - Network 0.031 6.94 
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Supplementary Table 3 – Patient demographic, behavioural, tumour and treatment characteristics by Carstairs quintiles 
Variable 
Total (Col. %) Frequencies of Carstairs 2001 quintiles (Col. %) Chi-
square 
p-value 
1 – Most 
affluent  
2 3 4 5 – Most 
deprived 
Whole cohort (Row %) 1,820 (100.0%) 241 (13.2%) 317 (17.4%) 325 (17.9%) 409 (22.5%) 528 (29.0%) - 
Age at diagnosis       0.470 
   Less than 45 99 (5.4%) 16 (6.6%) 23 (7.3%) 16 (4.9%) 21 (5.1%) 23 (4.4%)  
   45 to 54 288 (15.8%) 35 (14.5%) 44 (13.9%) 45 (13.9%) 68 (16.6%) 96 (18.2%)  
   55 to 64 592 (32.5%) 70 (29.1%) 105 (33.1%) 108 (33.2%) 140 (34.2%) 169 (32.0%)  
   65 to 74 551 (30.3%) 72 (29.9%) 90 (28.4%) 111 (34.2%) 108 (26.4%) 170 (32.2%)  
   75 and over 290 (15.9%) 48 (19.9%) 55 (17.4%) 45 (13.9%) 72 (17.6%) 70 (13.3%)  
Sex       0.440 
   Male 1,300 (71.4%) 161 (66.8%) 227 (71.6%) 236 (72.6%) 289 (70.7%) 387 (73.3%)  
   Female 520 (28.6%) 80 (33.2%) 90 (28.4%) 89 (27.4%) 120 (29.3%) 141 (26.7%)  
Smoking status       <0.001 
   Current smoker 1,134 (62.3%) 118 (49.0%) 173 (54.6%) 191 (58.8%) 256 (62.6%) 396 (75.0%)  
   Previous smoker 405 (22.3%) 60 (24.9%) 86 (27.1%) 68 (20.9%) 100 (24.5%) 91 (17.2%)  
   Never smoked 221 (12.1%) 56 (23.2%) 45 (14.2%) 50 (15.4%) 41 (10.0%) 29 (5.5%)  
   Not recorded 60 (3.3%) 7 (2.9%) 13 (4.1%) 16 (4.9%) 12 (2.9%) 12 (2.3%)  
Alcohol consumption       <0.001 
   Current (problem) drinker 496 (27.3%) 51 (21.2%) 77 (24.3%) 80 (24.6%) 108 (26.4%) 180 (34.1%)  
   Previous (problem) drinker 212 (11.7%) 25 (10.4%) 29 (9.2%) 49 (15.1%) 47 (11.5%) 62 (11.7%)  
   Occasional/never drank 891 (49.0%) 138 (57.3%) 164 (51.7%) 150 (46.2%) 198 (48.4%) 241 (45.6%)  
   Not recorded 221 (12.1%) 27 (11.2%) 47 (14.8%) 46 (14.2%) 56 (13.7%) 45 (8.5%)  
WHO performance status       0.003 
   Normal activity 825 (45.3%) 137 (56.9%) 169 (53.3%) 137 (42.3%) 177 (43.3%) 205 (38.8%)  
   Strenuous activity restricted 465 (25.6%) 54 (22.4%) 66 (20.8%) 94 (28.9%) 102 (24.9%) 149 (28.2%)  
   Up and about > 50%  137 (7.5%) 18 (7.5%) 23 (7.3%) 17 (5.2%) 33 (8.1%) 46 (8.7%)  
   Confined to bed/chair >50%  97 (5.3%) 8 (3.3%) 18 (5.7%) 22 (6.8%) 26 (6.4%) 23 (4.4%)  
   Not recorded 296 (16.3%) 24 (10.0%) 41 (12.9%) 55 (16.9%) 71 (17.4%) 105 (19.9%)  
Anatomical site       0.470 
   Lip 85 (4.7%) 11 (4.6%) 17 (5.4%) 18 (5.5%) 23 (5.6%) 16 (3.0%)  
   Larynx 584 (32.1%) 71 (29.5%) 102 (32.2%) 103 (31.7%) 143 (35.0%) 165 (31.3%)  
   Nasal cavity 85 (4.7%) 12 (5.0%) 14 (4.4%) 22 (6.8%) 15 (3.7%) 22 (4.2%)  
   Oral cavity 506 (27.8%) 76 (31.5%) 93 (29.3%) 78 (24.0%) 97 (23.7%) 162 (30.7%)  
   Oropharynx 323 (17.8%) 40 (16.6%) 53 (16.7%) 63 (19.4%) 69 (16.9%) 98 (18.6%)  
   Hypopharynx 119 (6.5%) 12 (5.0%) 19 (6.0%) 20 (6.2%) 35 (8.6%) 33 (6.3%)  
   Other/salivary gland 118 (6.5%) 19 (7.9%) 19 (6.0%) 21 (6.5%) 27 (6.6%) 32 (6.1%)  
Stage       0.023 
   I 383 (21.0%) 58 (24.1%) 85 (26.8%) 75 (23.1%) 73 (17.9%) 92 (17.4%)  
   II 369 (20.3%) 48 (19.9%) 62 (19.6%) 65 (20.0%) 88 (21.5%) 106 (20.1%)  
   III 273 (15.0%) 37 (15.4%) 42 (13.3%) 40 (12.3%) 80 (19.6%) 74 (14.0%)  
   IV 662 (36.4%) 79 (32.8%) 102 (32.2%) 125 (38.5%) 145 (35.5%) 211 (40.0%)  
   Unknown 133 (7.3%) 19 (7.9%) 26 (8.2%) 20 (6.2%) 23 (5.6%) 45 (8.5%)  
Treatment modality       0.064 
   Surgery only 477 (26.2%) 72 (29.9%) 83 (26.2%) 86 (26.5%) 106 (25.9%) 130 (24.6%)  
   Radiotherapy only 507 (27.9%) 74 (30.7%) 99 (31.2%) 98 (30.2%) 117 (28.6%) 119 (22.5%)  
   Surgery + radiotherapy 458 (25.2%) 59 (24.5%) 82 (25.9%) 73 (22.5%) 101 (24.7%) 143 (27.1%)  
   Chemo +/- radio +/- surgery 249 (13.7%) 23 (9.5%) 34 (10.7%) 48 (14.8%) 56 (13.7%) 88 (16.7%)  
   No treatment 129 (7.1%) 13 (5.4%) 19 (6.0%) 20 (6.2%) 29 (7.1%) 48 (9.1%)  
Network       <0.001 
   WoSCAN (West Scotland) 1,001 (55.0%) 85 (35.3%) 110 (34.7%) 149 (45.9%) 244 (59.7%) 413 (78.2%)  
   SCAN (East Scotland) 440 (24.2%) 83 (34.4%) 85 (26.8%) 108 (33.2%) 108 (26.4%) 56 (10.6%)  
   NOSCAN (North Scotland) 379 (20.8%) 73 (30.3%) 122 (38.5%) 68 (20.9%) 68 (20.9%) 59 (11.2%)  
 
 
